Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine trial in human volunteers. Malaria genes inserted into the NYVAC genome encoded proteins from all stages of the parasite's life cycle. Volunteers received three immunizations of two different dosages of NYVAC-Pf7. The vaccine was safe and well tolerated but variably immunogenic. While antibody responses were generally poor, cellular immune responses were detected in ú90% of the volunteers. Of the 35 volunteers challenged with the bite of 5 P. falciparum -infected Anopheles mosquitoes, 1 was completely protected, and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.
Malaria is a major world-wide infectious disease problem, ment of an effective malaria vaccine include antigenic diversity and variation of parasites and the hosts' genetic nonresponin which transmission by the Anopheles mosquito vector occurs siveness to parasite antigens or epitopes. Previous clinical phase throughout Africa, Asia, Oceania, and Latin America. It is I studies have emphasized candidate malaria vaccine preparaestimated that ú2 billion people live in malarious areas and tions designed to induce antibodies directed against the circumthat there were ú489 million clinical cases of malaria during sporozoite (CS) protein present on the surface of the sporozoite 1986 [1] . Of these, an estimated 234 million were due to Plasof the parasite [2 -4] . modium falciparum infection and resulted in ú2.3 million faImmunization with combinations of antigens derived from talities [1] . An effective malaria vaccine is urgently required all stages of the parasite's life cycle has been proposed as in many areas of the world where drug resistance is becoming a way to overcome antigenic variability and HLA-restricted more frequent. Major obstacles that have impeded the developimmune responses. Attenuated or inactivated strains of pathogenic viruses are suitable for the delivery of multiple genes and have been used successfully for vaccination against a variety cines. Replication-competent animal viruses, such as poxvirus,
The opinions and assertions contained herein are those of the authors and have been engineered as delivery systems for vaccine candidate are not to be construed as reflecting the views of the Department of the Army gene products [5, 6] . These vectors provide advantages over [5] . The vaccine prepaand consists of 7 P. falciparum full-length or nearly full-length ration in our study, NYVAC-Pf7, represents a new generation genes inserted into the NYVAC vector, as described [7] . All antiof multistage, multiantigen vaccines consisting of an attenuated gens included in the vaccine have been shown to provide some NYVAC vaccinia virus strain that expresses genes coding for level of protection in experimental models of malaria. The malaria genes inserted into the NYVAC vector are (1) sporozoite stage proteins expressed during the sporozoite (CSP, PfSSP2), liver antigens: CS and sporozoite surface protein 2 (SSP2); (2) liver (LSA1), blood (MSP1, SERA, AMA1), and sexual (Pfs25) stage antigen: LSA1; (3) asexual blood stage proteins: MSP1, stages of the parasite's life cycle [7] . In preclinical testing in AMA1, and SERA; and (4) sexual stage antigen: Pfs25. All genes rhesus monkeys, NYVAC-Pf7 was safe and well tolerated.
(except MSP1 and SERA) were isolated from the 3D7 strain of Antibodies that recognize sporozoites, liver, blood, and sexual P. falciparum. MSP1 and SERA genes were cloned from the Palo stages of P. falciparum were elicited [7] . The objective of the Alto and FCR3 genes, respectively, and are very similar in sepresent study was to evaluate the safety and immunogenicity quence to the 3D7 genes.
of NYVAC-Pf7 in human volunteers. We also evaluated the Assessment of safety and reactogenicity. Subjects were obprotective efficacy by experimental challenge with 5 P. falcipaserved for 20 min and evaluated at 1, 2, and 7 days after immunizarum -infected Anopheles mosquitoes in vaccinated volunteers.
tion. At each visit, reactogenicity was assessed by a physician and findings and complaints recorded and scored as follows: mild reactions (easily tolerated), moderate reactions (interferes with normal activity), or severe reactions (prevents normal activity and
Materials and Methods
requires physician intervention). Safety was determined by serial Subjects. Fifty-nine malaria-naive male and female volunteers laboratory evaluations at 2 days after immunization and 1 week (age, 18-45 years) were recruited through the Walter Reed Army prior to subsequent vaccine doses. Laboratory tests included CBC, Institute of Research Clinical Center. Potential volunteers provided serum biochemistries, and urinalysis. a medical history and underwent a physical examination with rouSerologic assays. Blood was obtained from each volunteer tine standard laboratory tests consisting of complete blood count before and 2 weeks after each immunization, and the serum was (CBC), serum biochemistries, urinalysis, and serologic tests to separated and stored frozen at 070ЊC until used. Vaccinia neutralexclude volunteers positive for human immunodeficiency virus, ization titers were obtained on pre-and postimmunization serum hepatitis C virus, or hepatitis B surface antigen. Women participatsamples and were performed at the Salk Institute, Government ing in this study had serum pregnancy tests (serum human choriServices Division (Swiftwater, PA) by the plaque reduction neuonic gonadotropin [b-HCG]) completed within 48 h prior to receivtralization assay. Results are reported as the dilution of sera that ing any of the vaccine doses. Volunteers were excluded from gives 50% reduction of plaque-forming units. participation if they had any significant pulmonary, cardiovascular, Antibody responses to malaria antigens were measured by hepatic, or renal functional abnormality, had previously undergone ELISA. Recombinant-expressed full-length antigens included a splenectomy, had a positive b-HCG test, had known allergies Pfs25 [8] and AMA1, corresponding to the 3D7 ectodomain. Reto eggs or egg products, had previous allergy or anaphylactic reaccombinant-expressed partial-length antigens included SERA tion to any vaccine, or had previous malaria infection. Prior immu-(SE47), encoding amino acid residues 17-382 [9] ; LSA1, Cnity to vaccinia was not an exclusionary criterion, and volunteers terminal fragment of LSA1 encoding amino acids 1628-1909 exwere stratified by history of smallpox vaccination. pressed as a [His]6-tagged protein in Escherichia coli; and the Study design and vaccine formulation. This study was an C-terminal 19-kDa fragment of MSP1 [10] . Synthetic peptides open-label phase I/IIa trial of two dosages of NYVAC-Pf7 comprising the immunodominant epitopes of the CS protein (40-(vP1209) with saline control. The vaccine preparations for this mer peptide composed of 10 repeating units of Asn-Asp-Asn-Pro study were manufactured in the United States under good manufacamino acids [NANP]10) and SSP2 (SPNPEEGKGENPNGFDLturing procedures by Connaught Laboratories. Two liquid prepara-DENPENPPNPPNPPNPPNPPNPPN) were synthesized by stantions bottled in single-dose vials were prepared such that one dose dard solid-phase methods and purified to ú90% by reverse-phase of 1.0 mL contained either Ç10 7 pfu (hereafter referred to as low high-pressure liquid chromatography. Criteria for seroconversion dose) or Ç10 8 pfu (hereafter referred to as high dose) of the required that the magnitude of the antibody response (kinetic mea-NYVAC-Pf7 (vP1209) vector. The vaccine was stored frozen at surement of optical density units per minute at A 405 for 1 h) ex-070ЊC until used. The vaccine was thawed for 30 min at room ceeded the mean plus 2 SD of baseline values (preimmunization temperature prior to injection. Twenty-five volunteers were immusera) from triplicate determinations of serum samples diluted nized with low-dose NYVAC-Pf7 vaccine intramuscularly in the 1:100. Sera were analyzed by indirect IFA assay using air-dried deltoid region of alternate arms at 0, 4, and 26 weeks. Twentysporozoites and air-dried and methanol-fixed schizont-stage, asexfour volunteers were immunized on the same schedule with highual, blood-stage parasites. End-point titers were read as the greatest dilution giving a 1/ reaction [11] . Functional activity of antibody dose NYVAC-Pf7 Ç12 weeks after the low-dose immunization responses to Pfs25 was determined by transmission-blocking Cloned P. falciparum 3D7 parasites were expanded from a master seed lot and used to infect laboratory-reared Anopheles stephensii. assays, as previously determined [8] .
Cytotoxic lymphocyte (CTL) assay. CTL assays were perThe malaria challenge phase of the study for the low-and highdose vaccine groups was separated by Ç11 weeks. Four weeks formed using antigen-pulsed autologous Epstein-Barr virus (EBV)-transformed B lymphocytes as target cells to predict putaafter the third inoculation, 19 low-dose subjects, 16 high-dose subjects, and 8 control volunteers consented to experimental infective CTL activity in vivo against parasite-infected hepatocytes. All volunteers' peripheral blood mononuclear cells (PBMC) were tion. Challenge continued until 5 infected mosquitoes had successfully fed. Mosquitoes harvested from the same batch fed on a tissue-typed for class I histocompatibility antigens. The methodology used to measure CTL responses induced by NYVAC-Pf7 imsubject for 5 min, and insects with blood meals were dissected to quantify the presence of viable sporozoites. Sporozoite burdens munization depended on HLA class I molecules, known CTL epitopes present within malaria antigens, the nature of the antigens were uniformly heavy throughout the challenge. Volunteers were followed daily for symptoms and with blood or peptides used as stimulators, and the nature of the target cells used for measurement of lytic activity.
smears between days 5 and 21 after challenge. Giemsa-stained thick smears from asymptomatic subjects were routinely screened PBMC obtained before the first dose and Ç2 weeks after each immunization were used to generate effector cells. PBMC were for 200 high-power fields before being reported as negative. For symptomatic volunteers, smears were examined exhaustively. All cultured in RPMI 1640 complete medium containing human AB serum and stimulated with either recombinant canarypox virus subjects with positive malaria smears were treated with a standard oral regimen of chloroquine plus other medications as indicated (ALVAC) constructs or defined malaria nonamer CTL peptide epitopes for 7 days before being assayed. The cultures were grown by the symptoms and followed daily until three consecutive thick smears were negative and all symptoms had resolved. in the presence of 25 ng/mL recombinant interleukin (IL)-7 and 10 U/mL recombinant IL-2. Malaria-specific CTL were assayed Statistical methods. The primary analysis compared the antibody responses to different vaccine component antigens among in a standard chromium release assay. Target cells were prepared by three methods: (1) cells were infected 24 h prior to assay volunteers receiving either the low or high dose of NYVAC-Pf7. In addition, antibody responses to parasite antigens were compared with recombinant vaccinia virus (WR strain) constructs containing individual malaria antigens CS, LSA1, and SSP2; (2) cells were in volunteers who had prior immunity to vaccinia or were immunologically naive to vaccinia virus exposure as determined by history, transfected with a plasmid containing SSP2 (DNA-SSP2) or a control plasmid (DNA-neo); and (3) cells were peptide-pulsed with physical examination, and preimmunization seroreactivity in plaque-neutralization assays. Mean ({SE) antibody responses after CS, SSP2, or LSA1 peptides (peptide sequences are available on request). In most cases, peptide-pulsed EBV-transformed cell lines each vaccination and antibody titers at day 0 were compared by two-sided paired t tests. Between-group differences (vaccine vs. were used as target cells to measure CTL activity and were selected depending on putative T cell epitopes corresponding to known saline, low vs. high dose, vaccinia-immune vs. vaccinia-naive) were assessed by two-sided t tests. To assess the time to seroconclass I HLA motifs. The cutoff value for positive CTL activity was set at 10% specific lysis above the value measured by lysis version or seroconversion rate for a given subject, the antibody titer from sera drawn after the first immunization was compared of control targets. Further controls included measuring CTL activity of PBMC collected from volunteers before immunization and with the antibody titer at day 0 for a significant increase (onesided t test, P õ .05). If there was not a statistically significant processed in an identical manner as PBMC collected after vaccine immunization.
response after immunization 1, the sera after immunization 2 or 3 were analyzed by the same method. If there was no response Lymphocyte proliferation assay. Lymphocyte proliferation was assayed as described [12] . Briefly, PBMC were cultured in after immunization 3, the subject was considered a nonresponder. Regression analysis was used to measure the relationship between triplicate (5 1 10 4 cells/well) in 96-well flat-bottomed microtiter plates in a final volume of 200 mL of RPMI 1640 supplemented the log of vaccinia neutralization titer at day 0 and the mean differences in postimmunization antimalaria antigen titers. Comwith 15 mM HEPES buffer, 10% fetal bovine serum, 8 mM glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 mg/mL parisons between times to positive malaria parasitemia were based on the Wilcoxon 2-sample test (normal approximation, continuity streptomycin, and 50 mM 2-mercaptoethanol for 7 days at 37ЊC in a humidified atmosphere with 5% CO 2 . The cells were stimucorrection of 0.5). lated with phytohemagglutinin (2 mg/mL), tuberculin purified protein derivative (2 mg/mL), CS or LSA1 peptide (0.1-10 mg/mL), munization dose. Volunteers were recruited with the intention following two NYVAC-Pf7 immunizations in volunteers without a history of prior smallpox vaccination (vaccinia-naive) to include persons who had a history of smallpox vaccination and/or physical evidence of scarification as an indicator of prior was low, confirming the highly attenuated nature of the vaccinia virus construct. immunity to vaccinia virus (vaccinia-immune) and to include subjects who had never received a smallpox vaccination (vacAntibody responses to full-length recombinant malaria antigens (Pfs25, AMA1) or to immunodominant epitopes from cinia-naive). The accuracy of the history and physical examination was validated by obtaining vaccinia neutralization antirecombinant fragments (LSA1, MSP1, SERA) or synthetic peptides (CS, SSP2) were analyzed by ELISA, indirect IFA, and body titers from preimmunization sera.
Safety and reactogenicity. All three immunizations of lowin some cases immunoprecipitation of metabolically labeled malaria-infected erythrocytes. The magnitude of antibody reand high-dose NYVAC-Pf7 were well tolerated; the most common side effect was local tenderness at the site of injection sponse (antibody titer) was assessed in an ELISA by the rate of change in optical density units per unit of time (kinetic rate), (table 1) . Transient ''flu-like'' symptoms, including pain, malaise, feverishness, chills, and headache, were reported in several volunteers who had received the high-dose NYVAC-Pf7 vaccine. All adverse reactions were classified as mild or moderate and occurred within 24 h of immunization. Most reactions had resolved by 72 h after immunization, and no reactions were reported after 7 days of follow-up. The frequency of adverse reactions peaked after the second dose of vaccine. There were no clinically relevant deviations in laboratory tests associated with the administration of either the low-or high-dose vaccine, and no skin ulcerations were noted at the site of inoculation. In addition, there was no relationship between vaccinia immune status at time of enrollment and vaccine reactogenicity after any of the three immunizations.
Antibody responses. All volunteers had vaccinia serology testing as determined by the sera dilution that gives 50% reduction in plaque-forming units. As expected, volunteers with prior exposure to vaccinia as children (vaccinia-immune) boosted their antibody responses after the first immunization with both SERA recombinant proteins [9] used in the ELISA. Control subjects who received saline alone did not seroconvert to any malaria antigen. in volunteers occurred after both the second and third immuniThe NYVAC-Pf7 high-dose vaccine was more immunogenic zation doses (figure 2). than the low-dose vaccine in that a greater proportion of volunAntibody responses by ELISA to blood-stage antigens MSP1 teers seroconverted to CS, LSA1, MSP1, and AMA1 (table 3) .
and AMA1 (figure 3) were low or not detected (SERA). PosiThere was no statistically significant difference in the magnitive IFA responses to malaria-infected erythrocytes were obtude of the antibody response between the low-and highserved in only 2 of 38 volunteers (1 from each dosage group). dose vaccine recipients, regardless of vaccinia immune status.
The antibody levels to MSP1 and AMA1, as measured by However, in subgroup analysis, there was a statistically sig-ELISA after immunization with NYVAC-Pf7, were low comnificant difference in the magnitude of antibody responses when pared with antibody levels measured in human volunteers after comparisons were based on prior vaccinia exposure due to a single infection of the 3D7 clone of P. falciparum (unantecedent smallpox vaccination. For example, antibody titers published observations). Nevertheless, immunization with to the CS repeat peptide and to sporozoites by IFA were highest NYVAC-Pf7 primed the immune system for increased serorein volunteers who had never had a history of smallpox vaccinaactivity of blood-stage antigens MSP1 and AMA1, as evition (vaccinia-naive) (figure 2). Furthermore, regression analydenced by increased antibody titers in sera drawn 2 weeks after sis revealed a significant inverse correlation between antimalar-P. falciparum infection and drug treatment compared with sera ial antibody titers (CS antigen, P Å .0001; Pfs25, P Å .004; from nonimmunized malaria-infected and drug-cured volun-SSP2, P Å .004) after three NYVAC-Pf7 immunizations and teers ( figure 3 ). This antibody response to blood-stage antigens antivaccinia neutralization titers at the time of study entry.
after malaria challenge and drug cure was dependent on both Antecedent vaccinia virus exposure during childhood did not the dose and vaccinia immune status. To determine whether prevent the subsequent ability of volunteers to respond to new the antibody response to MSP1 elicited by NYVAC-Pf7 and antigens with multiple immunizations. In fact, significant detected by ELISA was directed against native malaria protein, boosting in antibody titers and increased seroconversion rates detergent extracts of [ 35 S]methionine-labeled parasites grown in culture were immunoprecipitated with preimmune sera or sera drawn 2 weeks after administration of the high-dose vac- dose vaccine seroconverted to 6 of 7 antigens (figure 6B). Two Cell-mediated immune responses. Cell-mediated immune virus alone. In other cases, target cells were transfected with plasmid DNA encoding SSP2. The background lysis observed responses to NYVAC-Pf7 vaccination were evaluated by in vitro CTL assays and lymphoproliferative responses to antiin these assays prevented meaningful interpretation of specific cytolytic activity attributed exclusively to malaria-specific gen-based peptide sequences. Several approaches were used to evaluate CTL activity in volunteers. Autologous EBV-CTL compared with lytic activity attributed to immune response induced by infection with vaccinia. Therefore, repretransformed B cells from subjects infected with vaccinia constructs (WR strain) encoding individual CS, SSP2, or LSA1 sentative CTL assays were designed using HLA-matched volunteers and malaria antigen peptides with known HLAantigen were used as targets, and most of these assays were performed in the presence of the 51 Cr-unlabeled ''cold tarspecific motifs. On the basis of these results, CTL activity was detected in volunteers receiving either the low-or highgets'' (EBV-transformed B cell lines infected with parental vaccinia virus) to eliminate or lower lysis induced by vaccinia dose vaccine, but no activity was observed in PBMC collected Another measure of cellular immune reactivity was established by evaluating lymphoproliferative responses to preerythrocytic-stage peptides or parasitized erythrocytes. We have previously demonstrated that recognition of antigens normally associated with erythrocytic stages occurs in lymphocyte cultures from volunteers immunized with irradiated sporozoites but not in lymphocyte cultures from sporozoite-naive volunteers [12] . In the present study, we investigated whether volunteers immunized with NYVAC-Pf7 would recognize antigens associated with parasitized red blood cells. This assay provided additional meaningful information on the induction of immune responses to the asexual stage antigens. Since IFA responses to blood stage antigens were observed in only 2 volunteers, we assessed whether the NYVAC-Pf7 vaccine primed the cellular immune system to recognize blood stage antigens. Indeed, Ç50% of subjects responded to blood-stage malaria antigens according to proliferation assays, confirming that the antigens high-dose, 8 control) were challenged with 5 mosquitoes infected with the P. falciparum 3D7 clone for 5 min. One volunteer (low-dose, vaccinia immune) was completely protected against malaria challenge. All unimmunized control volunteers prior to the first immunization dose (table 3) . In addition, no became parasitemic on days 9 -12. There was a significant differences were observed with respect to vaccinia immune delay in prepatent period (time to detectable parasitemia on status. All individuals with demonstrated CTL activity reGiemsa-stained thick blood smear) among volunteers receiving sponded primarily after the second immunization dose, and both the low-dose and high-dose NYVAC-Pf7 vaccine (figure little CTL activity was observed after the third dose. CTL 6). There was no difference in prepatent period with respect to activity was not observed to ú1 antigen in any given volunvaccinia immune status, and there was no relationship between teer, reflecting the restricted genetic responsiveness of host delay in prepatent period and antibody titer, CTL activity, or lymphoproliferative responses. and known CTL epitopes of CS, SSP2, and LSA1 (table 4). vaccinia-naive vaccinated subjects.
Although detectable immune responses were elicited by NYVAC-Pf7 immunization, the level of immunity generated Discussion by this vaccine does not confer protection against malaria infection despite a delay in the prepatent period. We speculate that Attenuated virally vectored vaccines for parasitic diseases are attractive alternatives to more traditional approaches for genetic immunization with malaria-encoded plasmids will elicit similar low-level antibody responses in humans and that boostvaccine development. The interest in live-virus vaccinia vectors as vehicles for antigen delivery is based on the need to generate ing with appropriately adjuvanted recombinant proteins will be required for protective immunity. In contrast to immunization diverse cellular [13 -17] as well as humoral [14, 18 -23] immune responses that elicit protective immunity on infection.
with NYVAC-Pf7, immunization with the CS protein alone, which we recently demonstrated, is expressed on hepatitis B In particular, the prevention of infection with the malaria parasite, P. falciparum, poses daunting challenges to vaccinologists.
surface antigen particles and, administered with a cocktail of three potent adjuvants, elicits a high degree of protective immuThe complexities associated with developing antimalarial vaccines include the diverse antigenic repertoire associated with nity [4] with significantly higher antibody levels to CS protein by both ELISA and IFA compared with sera from subjects the organism's many life-cycle changes, antigenic variation and diversity of wild-type isolates, intracellular development immunized with NYVAC-Pf7 (data not shown). NYVAC-Pf7 was designed principally to elicit cell-mediated (hepatocyte and erythrocyte), and restricted host genetic responsiveness. In this context, NYVAC-Pf7 offers the first immune responses directed toward the intrahepatic stages of the malaria parasite, and in this context, it was successful. The multistage, multicomponent vaccine against any infectious disease to test the concept that attenuated live-virus vectors are safe, immunogenic, and efficacious.
NYVAC-Pf7 proved to be a well-tolerated vaccine, and the Since it has not been previously known whether repeated . Currently, we are investigating the primeboost strategy in primate models of P. falciparum malaria using induced protection in animals and human volunteers exposed to experimental malaria challenge [24, 25] . The relevance of attenuated live virus vectors (NYVAC and ALVAC) followed by boosting with multiple recombinant proteins or naked DNA the detection of CTL in peripheral circulation with regard to malaria immunity is uncertain. Indeed, in the murine model of vectors to enhance immunogenicity. In summary, NYVAC-Pf7 proved to be safe, well tolerated, and immunogenic for multiple Plasmodium berghei malaria, immunization with NYVAC-CS conferred protection in ú80% of mice, and this protection was antigens. Future formulations will require additional measures to boost immunogenicity prior to advanced development in afforded by CD8 cells [26] . In this context, it is significant that circulating CTL activity was detected in volunteers not human vaccine trials. protected from malaria challenge and no CTL activity was detected in the lone volunteer protected against the infection.
